Literature DB >> 32321755

LILRB1 Intron 1 Has a Polymorphic Regulatory Region That Enhances Transcription in NK Cells and Recruits YY1.

Kang Yu1, Chelsea E Davidson1, Deborah N Burshtyn2,3,4.   

Abstract

LILRB1 is a highly polymorphic receptor expressed by subsets of innate and adaptive immune cells associated with viral and autoimmune diseases and targeted by pathogens for immune evasion. LILRB1 expression on human NK cells is variegated, and the frequency of LILRB1+ cells differs among people. However, little is known about the processes and factors mediating LILRB1 transcription in NK cells. LILRB1 gene expression in lymphoid and myeloid cells arises from two distinct promoters that are separated by the first exon and intron. In this study, we identified a polymorphic 3-kb region within LILRB1 intron 1 that is epigenetically marked as an active enhancer in human lymphoid cells and not monocytes. This region possesses multiple YY1 sites, and complexes of the promoter/enhancer combination were isolated using anti-YY1 in chromatin immunoprecipitation-loop. CRISPR-mediated deletion of the 3-kb region lowers LILRB1 expression in human NKL cells. Together, these results indicate the enhancer in intron 1 binds YY1 and suggest YY1 provides a scaffold function enabling enhancer function in regulating LILRB1 gene transcription in human NK cells.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Year:  2020        PMID: 32321755     DOI: 10.4049/jimmunol.2000164

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Natural LILRB1 D1-D2 variants show frequency differences in populations and bind to HLA class I with various avidities.

Authors:  Fuguo Liu; Alexander T H Cocker; Jason L Pugh; Zakia Djaoud; Peter Parham; Lisbeth A Guethlein
Journal:  Immunogenetics       Date:  2022-05-13       Impact factor: 3.330

Review 2.  Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer.

Authors:  Mi Deng; Heyu Chen; Xiaoye Liu; Ryan Huang; Yubo He; Byounggyu Yoo; Jingjing Xie; Samuel John; Ningyan Zhang; Zhiqiang An; Cheng Cheng Zhang
Journal:  Antib Ther       Date:  2021-02-09

3.  Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells.

Authors:  Heyu Chen; Yuanzhi Chen; Mi Deng; Samuel John; Xun Gui; Ankit Kansagra; Weina Chen; Jaehyup Kim; Cheryl Lewis; Guojin Wu; Jingjing Xie; Lingbo Zhang; Ryan Huang; Xiaoye Liu; Hisashi Arase; Yang Huang; Hai Yu; Wenxin Luo; Ningshao Xia; Ningyan Zhang; Zhiqiang An; Cheng Cheng Zhang
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.